Do you want to read an article? Please log in or register.
Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy
Lymphoma
Related content
COMMENTED
Lymphoma
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1056/NEJMoa1914347.
Lymphoma
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Cancer Med.
Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B
doi: 10.1002/cam4.939
Genitourinary CancerSkin Cancer
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
J Clin Oncol.
Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M1, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD
doi: 10.1200/JCO.2017.75.1644.
RECOMMENDED
Lymphoma
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
★ 3
Recommended by
Alexander Meisel, Faculty Member
Lancet Haematol.
Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, Diefenbach CS, Feldman TA, Ansell SM
doi: 10.1016/S2352-3026(20)30275-1.Visit the original publication at ncbi.nlm.nih.gov
Lymphoma
Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up
Leuk Lymphoma.
Jurczak W, M Gruszka A, Sowa Staszczak A, Dlugosz-Danecka M, Szostek M, Zimowska-Curylo D, Giza A, Krawczyk K, Jakobczyk M, Hubalewska-Dydejczyk A, Szymczyk M, Wróbel T, Knopińska-Posłuszny W, Kisiel E, Skotnicki A, Zinzani PL
doi: 10.1080/10428194.
Lymphoma
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Lancet Haematol.
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM
doi: 10.1016/S2352-3026(20)30221-0.
Breast Cancer
Breast Cancer Treatment in the Era of Precision Medicine
1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
Lymphoma
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
Leuk Lymphoma.
Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH
doi: 10.1080/
Lymphoma
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
J Clin Oncol.
Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL
doi: 10.1200/JCO.19.02104.